Los Angeles Capital Management
AMRX icon

Los Angeles Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Los Angeles Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.6K Sell
772
-193,965
-100% -$2.6M ﹤0.01% 1965
2025
Q4 		$1.95M Sell
194,737
-35,733
-16% -$409K 0.01% 450
2025
Q3 		$2.31M Buy
230,470
+31,423
+16% +$282K 0.01% 465
2025
Q2 		$1.61M Buy
199,047
+140,150
+238% +$1.06M 0.01% 499
2025
Q1 		$494K Buy
+58,897
New +$492K ﹤0.01% 746
2023
Q4 		– Sell
-209,580
Closed -$884K – 1128
2023
Q3 		$884K Buy
209,580
+39,940
+24% +$149K ﹤0.01% 680
2023
Q2 		$526K Sell
169,640
-16,156
-9% -$34.4K ﹤0.01% 841
2023
Q1 		$258K Sell
185,796
-7,049
-4% -$14K ﹤0.01% 1060
2022
Q4 		$384K Sell
192,845
-10,150
-5% -$22.8K ﹤0.01% 962
2022
Q3 		$410K Sell
202,995
-1,340
-0.7% -$3.75K ﹤0.01% 979
2022
Q2 		$650K Buy
204,335
+28,604
+16% +$104K ﹤0.01% 866
2022
Q1 		$733K Sell
175,731
-1,900
-1% -$8.41K ﹤0.01% 885
2021
Q4 		$851K Sell
177,631
-3,279
-2% -$16.3K ﹤0.01% 778
2021
Q3 		$966K Buy
180,910
+6,490
+4% +$32.7K ﹤0.01% 776
2021
Q2 		$893K Buy
174,420
+115,870
+198% +$659K ﹤0.01% 906
2021
Q1 		$394K Buy
58,550
+34,515
+144% +$191K ﹤0.01% 1320
2020
Q4 		$110K Hold
24,035
– – ﹤0.01% 1495
2020
Q3 		$93K Hold
24,035
– – ﹤0.01% 1422
2020
Q2 		$114K Sell
24,035
-7,565
-24% -$31.2K ﹤0.01% 1427
2020
Q1 		$110K Buy
+31,600
New +$134K ﹤0.01% 1287

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Los Angeles Capital Management's AMRX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Amneal Pharmaceuticals (AMRX) stake by 100% in Q1 2026, selling an estimated $2.6M and leaving 772 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Los Angeles Capital Management first reported a position in AMRX in Q1 2020 and has held it in 20 quarters since. The position peaked at $2.31M in Q3 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Los Angeles Capital Management held 772 shares of Amneal Pharmaceuticals worth $9.6K as of Q1 2026.
  • Los Angeles Capital Management sold 193,965 Amneal Pharmaceuticals shares in Q1 2026, an estimated $2.6M.
  • Amneal Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1965 holding.
  • Los Angeles Capital Management first reported a position in Amneal Pharmaceuticals in Q1 2020 and has held it in 20 quarters since.
  • Los Angeles Capital Management's Amneal Pharmaceuticals position peaked at $2.31M in Q3 2025.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.